 | • レポートコード：MRC23Q35922 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、85ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の結晶性関節炎治療市場について調査・分析し、世界の結晶性関節炎治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（経口剤、注射剤）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Johnson & Johnson Services, Inc.、Zydus Cadila、Takeda Pharmaceutical Company Limited、Genentech, Inc.、Latona Life Sciences、Novartis AG、Merck & Co., Inc.、Bristol-Myers Squibb、GlaxoSmithKline plc、Savient Pharmaceuticals, Inc,.などが含まれています。 世界の結晶性関節炎治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、結晶性関節炎治療市場規模を推定する際に考慮しました。本レポートは、結晶性関節炎治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、結晶性関節炎治療に関するビジネス上の意思決定に役立てることを目的としています。 ・結晶性関節炎治療市場の概要 - 結晶性関節炎治療のタイプ別セグメント - 世界の結晶性関節炎治療市場規模：タイプ別分析（経口剤、注射剤） - 結晶性関節炎治療の用途別セグメント - 世界の結晶性関節炎治療市場規模：用途別分析（病院、薬局、その他） - 世界の結晶性関節炎治療市場規模予測（2018年-2029年） ・結晶性関節炎治療市場の成長トレンド - 結晶性関節炎治療の地域別市場規模（2018年-2029年） - 結晶性関節炎治療市場ダイナミクス - 結晶性関節炎治療の業界動向 - 結晶性関節炎治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：経口剤、注射剤 - 世界の結晶性関節炎治療のタイプ別市場規模（2018年-2023年） - 世界の結晶性関節炎治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、薬局、その他 - 世界の結晶性関節炎治療の用途別市場規模（2018年-2023年） - 世界の結晶性関節炎治療の用途別市場規模（2024年-2029年） ・結晶性関節炎治療の地域別市場規模 - 北米の結晶性関節炎治療市場規模（2018年-2029年） - アメリカの結晶性関節炎治療市場規模（2018年-2029年） - ヨーロッパの結晶性関節炎治療市場規模（2018年-2029年） - アジア太平洋の結晶性関節炎治療市場規模（2018年-2029年） - 中国の結晶性関節炎治療市場規模（2018年-2029年） - 日本の結晶性関節炎治療市場規模（2018年-2029年） - 韓国の結晶性関節炎治療市場規模（2018年-2029年） - インドの結晶性関節炎治療市場規模（2018年-2029年） - オーストラリアの結晶性関節炎治療市場規模（2018年-2029年） - 中南米の結晶性関節炎治療市場規模（2018年-2029年） - 中東・アフリカの結晶性関節炎治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Johnson & Johnson Services, Inc.、Zydus Cadila、Takeda Pharmaceutical Company Limited、Genentech, Inc.、Latona Life Sciences、Novartis AG、Merck & Co., Inc.、Bristol-Myers Squibb、GlaxoSmithKline plc、Savient Pharmaceuticals, Inc,. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Crystal-Induced Arthritides Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Crystal-Induced Arthritides Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Crystal-Induced Arthritides Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Crystal-Induced Arthritides Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Crystal-Induced Arthritides Treatment include Johnson & Johnson Services, Inc., Zydus Cadila, Takeda Pharmaceutical Company Limited, Genentech, Inc., Latona Life Sciences, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb and GlaxoSmithKline plc, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Crystal-Induced Arthritides Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Crystal-Induced Arthritides Treatment.
The Crystal-Induced Arthritides Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Crystal-Induced Arthritides Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Crystal-Induced Arthritides Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Johnson & Johnson Services, Inc.
Zydus Cadila
Takeda Pharmaceutical Company Limited
Genentech, Inc.
Latona Life Sciences
Novartis AG
Merck & Co., Inc.
Bristol-Myers Squibb
GlaxoSmithKline plc
Savient Pharmaceuticals, Inc,.
Segment by Type
Oral
Injectable
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Crystal-Induced Arthritides Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Crystal-Induced Arthritides Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Injectable
1.3 Market by Application
1.3.1 Global Crystal-Induced Arthritides Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Crystal-Induced Arthritides Treatment Market Perspective (2018-2029)
2.2 Crystal-Induced Arthritides Treatment Growth Trends by Region
2.2.1 Global Crystal-Induced Arthritides Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Crystal-Induced Arthritides Treatment Historic Market Size by Region (2018-2023)
2.2.3 Crystal-Induced Arthritides Treatment Forecasted Market Size by Region (2024-2029)
2.3 Crystal-Induced Arthritides Treatment Market Dynamics
2.3.1 Crystal-Induced Arthritides Treatment Industry Trends
2.3.2 Crystal-Induced Arthritides Treatment Market Drivers
2.3.3 Crystal-Induced Arthritides Treatment Market Challenges
2.3.4 Crystal-Induced Arthritides Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Crystal-Induced Arthritides Treatment Players by Revenue
3.1.1 Global Top Crystal-Induced Arthritides Treatment Players by Revenue (2018-2023)
3.1.2 Global Crystal-Induced Arthritides Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Crystal-Induced Arthritides Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Crystal-Induced Arthritides Treatment Revenue
3.4 Global Crystal-Induced Arthritides Treatment Market Concentration Ratio
3.4.1 Global Crystal-Induced Arthritides Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Crystal-Induced Arthritides Treatment Revenue in 2022
3.5 Crystal-Induced Arthritides Treatment Key Players Head office and Area Served
3.6 Key Players Crystal-Induced Arthritides Treatment Product Solution and Service
3.7 Date of Enter into Crystal-Induced Arthritides Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Crystal-Induced Arthritides Treatment Breakdown Data by Type
4.1 Global Crystal-Induced Arthritides Treatment Historic Market Size by Type (2018-2023)
4.2 Global Crystal-Induced Arthritides Treatment Forecasted Market Size by Type (2024-2029)
5 Crystal-Induced Arthritides Treatment Breakdown Data by Application
5.1 Global Crystal-Induced Arthritides Treatment Historic Market Size by Application (2018-2023)
5.2 Global Crystal-Induced Arthritides Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Crystal-Induced Arthritides Treatment Market Size (2018-2029)
6.2 North America Crystal-Induced Arthritides Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Crystal-Induced Arthritides Treatment Market Size by Country (2018-2023)
6.4 North America Crystal-Induced Arthritides Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Crystal-Induced Arthritides Treatment Market Size (2018-2029)
7.2 Europe Crystal-Induced Arthritides Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Crystal-Induced Arthritides Treatment Market Size by Country (2018-2023)
7.4 Europe Crystal-Induced Arthritides Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Crystal-Induced Arthritides Treatment Market Size (2018-2029)
8.2 Asia-Pacific Crystal-Induced Arthritides Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Crystal-Induced Arthritides Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Crystal-Induced Arthritides Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Crystal-Induced Arthritides Treatment Market Size (2018-2029)
9.2 Latin America Crystal-Induced Arthritides Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Crystal-Induced Arthritides Treatment Market Size by Country (2018-2023)
9.4 Latin America Crystal-Induced Arthritides Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Crystal-Induced Arthritides Treatment Market Size (2018-2029)
10.2 Middle East & Africa Crystal-Induced Arthritides Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Crystal-Induced Arthritides Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Crystal-Induced Arthritides Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson Services, Inc.
11.1.1 Johnson & Johnson Services, Inc. Company Detail
11.1.2 Johnson & Johnson Services, Inc. Business Overview
11.1.3 Johnson & Johnson Services, Inc. Crystal-Induced Arthritides Treatment Introduction
11.1.4 Johnson & Johnson Services, Inc. Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.1.5 Johnson & Johnson Services, Inc. Recent Development
11.2 Zydus Cadila
11.2.1 Zydus Cadila Company Detail
11.2.2 Zydus Cadila Business Overview
11.2.3 Zydus Cadila Crystal-Induced Arthritides Treatment Introduction
11.2.4 Zydus Cadila Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.2.5 Zydus Cadila Recent Development
11.3 Takeda Pharmaceutical Company Limited
11.3.1 Takeda Pharmaceutical Company Limited Company Detail
11.3.2 Takeda Pharmaceutical Company Limited Business Overview
11.3.3 Takeda Pharmaceutical Company Limited Crystal-Induced Arthritides Treatment Introduction
11.3.4 Takeda Pharmaceutical Company Limited Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.3.5 Takeda Pharmaceutical Company Limited Recent Development
11.4 Genentech, Inc.
11.4.1 Genentech, Inc. Company Detail
11.4.2 Genentech, Inc. Business Overview
11.4.3 Genentech, Inc. Crystal-Induced Arthritides Treatment Introduction
11.4.4 Genentech, Inc. Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.4.5 Genentech, Inc. Recent Development
11.5 Latona Life Sciences
11.5.1 Latona Life Sciences Company Detail
11.5.2 Latona Life Sciences Business Overview
11.5.3 Latona Life Sciences Crystal-Induced Arthritides Treatment Introduction
11.5.4 Latona Life Sciences Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.5.5 Latona Life Sciences Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Detail
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Crystal-Induced Arthritides Treatment Introduction
11.6.4 Novartis AG Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.6.5 Novartis AG Recent Development
11.7 Merck & Co., Inc.
11.7.1 Merck & Co., Inc. Company Detail
11.7.2 Merck & Co., Inc. Business Overview
11.7.3 Merck & Co., Inc. Crystal-Induced Arthritides Treatment Introduction
11.7.4 Merck & Co., Inc. Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.7.5 Merck & Co., Inc. Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Crystal-Induced Arthritides Treatment Introduction
11.8.4 Bristol-Myers Squibb Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 GlaxoSmithKline plc
11.9.1 GlaxoSmithKline plc Company Detail
11.9.2 GlaxoSmithKline plc Business Overview
11.9.3 GlaxoSmithKline plc Crystal-Induced Arthritides Treatment Introduction
11.9.4 GlaxoSmithKline plc Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.9.5 GlaxoSmithKline plc Recent Development
11.10 Savient Pharmaceuticals, Inc,.
11.10.1 Savient Pharmaceuticals, Inc,. Company Detail
11.10.2 Savient Pharmaceuticals, Inc,. Business Overview
11.10.3 Savient Pharmaceuticals, Inc,. Crystal-Induced Arthritides Treatment Introduction
11.10.4 Savient Pharmaceuticals, Inc,. Revenue in Crystal-Induced Arthritides Treatment Business (2018-2023)
11.10.5 Savient Pharmaceuticals, Inc,. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details